[ad_1]
LAST UPDATE: 22:19
One of the volunteers who participated in the clinical trial of the vaccine developed by the company AstraZeneca and the University of Oxford for Covid-19 has died, announced the Brazilian health service Anvisa.
The service did not specify the volunteer’s citizenship. However, according to the University of Sao Paulo, which helps coordinate the third phase of the clinical trial, he was Brazilian.
However, according to the country’s Anvisa health service, the clinical trial of the vaccine being developed by the pharmaceutical company AstraZeneca in collaboration with the University of Oxford will continue in Brazil, despite the death of a volunteer. The service did not provide further details on the death of the volunteer, citing the secrecy of the protocols.
A source with knowledge of the situation then stated that the clinical trial of the vaccine of the pharmaceutical company AstraZeneca and the University of Oxford in Brazil would have stopped if the deceased volunteer had participated in its active part.
This statement may mean that the volunteer participated in the control group, that is, they did not receive the Covid-19 vaccine but another vaccine against meningitis. Bloomberg also reported that the volunteer had not received the experimental vaccine for the new coronavirus.
The test participants do not know which group they belong to, whether they are receiving the vaccine or a placebo.
Astrazeneca’s stock is currently reacting down around 1%.
However, health experts have raised concerns about AstraZeneca’s vaccine trials, as the company temporarily suspended a clinical trial in Britain twice as two people who participated in it showed serious neurological problems. disease.
Experts have even expressed fear that if a third case of a patient with a neurological disease is reported, the drug company could be forced to write “final titles” in an effort to develop a pandemic vaccine.
It should be noted that the company is conducting clinical trials of its vaccine in Britain, Brazil, India and South Africa, while some 18,000 people worldwide have received its vaccine. The clinical trial that the company had started in the US has been temporarily stopped.
With information from ΑΠΕ-ΜΠΕ
